Boston Scientific Corporation 2. Çeyrek 2026 Kazanç Çağrısı Özeti

Boston Scientific Corporation Q2 2026 Earnings Call Summary

Moby Intelligence

Thu, July 30, 2026 at 12:55 AM GMT+3 3 min read

Boston Scientific Corporation Q2 2026 Earnings Call Summary - Moby

Performance Attribution and Strategic Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributed the Q2 performance beat to strength in Interventional Cardiology, Endoscopy, and Neuromodulation, though results were offset by a sharp slowdown in the Left Atrial Appendage Closure (LAAC) market.
The WATCHMAN franchise faced unexpected headwinds as compounding clinical evidence regarding stroke risk impacted patient referral patterns and identification.
In the U.S. Electrophysiology (EP) market, management acknowledged underestimating the degree of competitive share movement as the market transitioned to Pulsed Field Ablation (PFA) faster than anticipated.
Approximately 75% of the company's business units, including Interventional Oncology and Vascular Therapies, continue to grow at a steady 6% rate, consistent with historical performance.
Urology performance fell short of expectations due to a slower-than-anticipated recovery in the sacral neuromodulation business and portfolio gaps in stone management.
Operational margins were impacted by less favorable product mix from lower-margin sales in WATCHMAN and EP, alongside incremental investments in supply chain and quality systems.

Strategic Outlook and 2028 Recovery Framework

Full year 2026 organic revenue guidance was lowered to 5% to 6%, reflecting an assumption that current market challenges in WATCHMAN and EP will persist through 2027.
Management expects 2027 to be a transition year with limited adjusted EPS growth and continued margin pressure before a projected return to high performance in 2028.
The 2028 recovery is predicated on seven major product launches across a $25 billion total addressable market, including IVL, renal denervation, and the integration of Penumbra.
A new restructuring program aims to deliver $500 million in run-rate savings by the end of 2029 to fund strategic reinvestments and support future EPS growth.
The company anticipates potentially re-entering the TAVR market in 2028 through its investment in MiRus, pending the achievement of clinical and regulatory milestones and the exercise of its acquisition option.

Structural Changes and Risk Factors

The company announced a comprehensive restructuring program focused on supply chain optimization and organizational evolution to drive sustained cost efficiencies.
The pending acquisition of Penumbra is expected to close in the second half of 2026, though it is projected to be slightly dilutive to operating margins and EPS initially.
A $75 million GAAP charge was recorded related to product liability cases, partially offset by $80 million in refunds from previously paid IEEPA tariffs.
Management flagged a 20% cut to physician fees and new competition as potential headwinds for the WATCHMAN franchise entering 2027.

Q&A Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Drivers of the WATCHMAN market slowdown and recovery strategy

Management noted a drop-off in 'soft indications' where patients without well-defined bleeding risks are being kept on oral anticoagulants due to recent clinical study confusion.
The recovery strategy involves expanded physician education, increased direct-to-patient investment, and the upcoming SIMPLAAFY trial to simplify post-procedure drug regimens.

Competitive dynamics and share loss in U.S. Electrophysiology

Management admitted to losing share in the U.S. as PFA now represents 80% to 85% of the atrial fibrillation market, limiting the ability to offset competitive entries.
Growth is expected to remain flat until the second half of 2027, when the launch of the FARAWAVE Ultra and entry into the ICE imaging market are slated to occur.

Restructuring impact on the P&L through 2027

Savings will initially materialize in SG&A followed by COGS, with over half of the $500 million run-rate savings expected to be realized by the end of 2027.
The program is designed to protect funding for high-growth R&D while offsetting the margin impact of a less favorable product mix.